Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections

Author: Uh Jin KIM ¹ ; Hee Kyung KIM ; Joon Hwan AN ; Soo Kyung CHO ; Kyung Hwa PARK ; Hee Chang JANG
Author Information

1. Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea. haroc153@naver.com
Publication Type:Review
Keywords: Acinetobacter baumannii; Colistin; Drug therapy
MeSH: Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Colistin; Critical Illness; Drug Therapy; Epidemiology; Humans; Infection Control; Critical Care
From:Chonnam Medical Journal 2014;50(2):37-44
CountryRepublic of Korea
Language:English
Abstract: Carbapenem-resistant Acinetobacter species are increasingly recognized as major nosocomial pathogens, especially in patients with critical illnesses or in intensive care. The ability of these organisms to accumulate diverse mechanisms of resistance limits the available therapeutic agents, makes the infection difficult to treat, and is associated with a greater risk of death. In this review, we provide an update on the epidemiology, resistance mechanisms, infection control measures, treatment, and outcomes of carbapenem-resistant Acinetobacter infections.